公开(公告)号：US20210236730A1

公开(公告)日：2021-08-05

申请号：US17166072

申请日：2021-02-03

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Yibin ZHENG ,  Steven CARDINALI

IPC: A61M5/172 ,  G16H20/17 ,  G16H10/60 ,  G16H20/30 ,  G16H50/20

Abstract: In an automated insulin delivery device, fuzzy logic may be applied to the responding to the possibility of a user taking additional action that may affect the blood glucose concentration. Fuzzy sets may be defined for empirically derived different likelihoods of the user taking such additional action based on correlated factors. A membership function may be provided for each fuzzy set. The membership function may provide a probability of membership in the set based on a parameter. Each fuzzy set may have a response that is reflective of the likelihood of additional user action associated with the fuzzy set. The responses by the AID device to each of these cases may reflect the probability of each such case occurring as evidenced by empirical data.

公开(公告)号：US20210187197A1

公开(公告)日：2021-06-24

申请号：US17123378

申请日：2020-12-16

Applicant: Insulet Corporation

Inventor： Ashutosh ZADE ,  Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142 ,  G16H20/17

Abstract: Disclosed are devices, a system, methods and computer-readable medium products that provide techniques to implement functionality to determine when to softened upper bounds of drug delivery and how much to soften the upper bound. Future blood glucose measurement values may be predicted by calculating deviations between predicted blood glucose measurement values and additional blood glucose measurement values. A gain parameter may be determined for use with a model of predicting a user's blood glucose measurement values and determining future drug dosages. Safety constraints may be determined based on an evaluation of missing blood glucose measurement values. In addition, safety constraints may be determined based on an evaluation of a user's increased interaction with an automatic drug delivery device. A bolus uncertainty metric to determine an amount of insulin to be provided in a bolus dosage in response to a bolus request may be calculated.

公开(公告)号：US20210170104A1

公开(公告)日：2021-06-10

申请号：US17112314

申请日：2020-12-04

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Steven CARDINALI ,  Jason O'CONNOR ,  Eric BENJAMIN ,  Ian MCLAUGHLIN ,  David NAZZARO ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G16H40/67 ,  G16H20/17 ,  G16H50/70 ,  G16H10/60 ,  G16H50/30 ,  G16H40/40 ,  G16H20/60 ,  G01N33/49

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US20250132007A1

公开(公告)日：2025-04-24

申请号：US18909496

申请日：2024-10-08

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Yibin ZHENG ,  Jason O’CONNOR

IPC: G16H20/17 ,  A61M5/142 ,  A61M5/172

Abstract: A medicament delivery system, process and techniques are provided. The medicament delivery system may include a wearable medicament delivery device, a memory storing programming instructions, and a processor. The processor may be operable to execute the programming instructions, which cause the processor to receive an available medicament delivery history of a user, and determine whether the available medicament delivery history spans an extent of time greater than a first glucose history duration. The processor, in response to a determination that the extent of time spanned by the available medicament delivery history is greater than the first glucose history duration, determines an average daily medicament delivered. The processor calculates a trust value of the available medicament delivery history, and utilizes the trust value to determine a total daily medicament value of the user.

公开(公告)号：US20250050021A1

公开(公告)日：2025-02-13

申请号：US18797048

申请日：2024-08-07

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  William WHITELEY ,  Jason O’CONNOR

IPC: A61M5/172 ,  G16H20/17

Abstract: Exemplary embodiments may configure the glucose cost component of a cost function used in determining basal insulin delivery doses to be limited by the maximum physiological rate of glucose level change over a time period so that the cost function more accurately reflects the physical limits of change due to insulin action, As a result, the glucose cost component of the cost function may more accurately reflect the response of a user to basal insulin deliveries, resulting in better insulin control for the user. Exemplary embodiments may modify the aggressiveness of a control approach based on a current target glucose level versus a nominal target glucose level for which the control approach was designed.

公开(公告)号：US20240399059A1

公开(公告)日：2024-12-05

申请号：US18804372

申请日：2024-08-14

Applicant: INSULET CORPORATION

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US20240325640A1

公开(公告)日：2024-10-03

申请号：US18618579

申请日：2024-03-27

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  John D’ARCO ,  Yibin ZHENG ,  Jason O’CONNOR

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17

Abstract: A drug delivery system including a memory storing programming code operable to control delivery of a drug, a user interface operable to accept an input indicating a perceived glucose state of a user, and a processor operable to execute the programming code. When executed, the programming code causes the processor to: receive a perceived state signal from the user interface indicating the perceived glucose state of the user, evaluate the perceived glucose state of the user indicated by the perceived state signal using a glucose measurement value corresponding in time to when the perceived state signal was received, determine an adjustment to a drug delivery algorithm, and utilize the adjustment in a determination of a drug delivery dosage to be administered to a user.

公开(公告)号：US20240307618A1

公开(公告)日：2024-09-19

申请号：US18675900

申请日：2024-05-28

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR

IPC: A61M5/172 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61M5/14244 ,  A61M2205/52 ,  A61M2230/201

Abstract: Exemplary embodiments provide an approach to predicting meal and/or exercise events for an insulin delivery system that otherwise does not otherwise identify such events. The insulin delivery system may use a model of glucose insulin interactions that projects estimated future glucose values based on the history of glucose values and insulin deliveries for the user. The predictions of meal events and/or exercise events may be based on residuals between actual glucose values and predicted glucose values. The exemplary embodiments may calculate a rate of change of the residuals over a period of time and compare the rate of change to thresholds to determine whether there likely has been a meal event or an exercise event. The insulin delivery system may then take measures to account for the meal or exercise by the user.

公开(公告)号：US20240252753A1

公开(公告)日：2024-08-01

申请号：US18633816

申请日：2024-04-12

Applicant: INSULET CORPORATION

Inventor： Yibin ZHENG ,  Joon Bok LEE ,  Steven CARDINALI ,  Jason O'CONNOR ,  Eric BENJAMIN ,  Ian MCLAUGHLIN ,  David NAZZARO ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61M5/142 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70

CPC classification number: A61M5/1723 ,  A61M5/14248 ,  G01N33/49 ,  G16H10/60 ,  G16H20/17 ,  G16H20/60 ,  G16H40/40 ,  G16H40/67 ,  G16H50/30 ,  G16H50/70 ,  A61M2005/1726 ,  A61M2205/505 ,  A61M2205/52 ,  A61M2230/201

Abstract: Disclosed are a device, system, methods and computer-readable medium products that provide an updated insulin-to-carbohydrate ratio and an updated total daily insulin. The described processes may be used for periodic updating of the insulin-to-carbohydrate ratio and the total daily insulin. The insulin-to-carbohydrate ratio and/or the total may be used in the calculation of new doses of insulin that a drug delivery device may be commanded to deliver to a user.

公开(公告)号：US20240252751A1

公开(公告)日：2024-08-01

申请号：US18629121

申请日：2024-04-08

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  A61M2230/63

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.